HRP20231497T1 - Makrociklični antibiotici širokog spektra - Google Patents
Makrociklični antibiotici širokog spektra Download PDFInfo
- Publication number
- HRP20231497T1 HRP20231497T1 HRP20231497TT HRP20231497T HRP20231497T1 HR P20231497 T1 HRP20231497 T1 HR P20231497T1 HR P20231497T T HRP20231497T T HR P20231497TT HR P20231497 T HRP20231497 T HR P20231497T HR P20231497 T1 HRP20231497 T1 HR P20231497T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- methyl
- hydroxy
- compound
- pharmaceutically acceptable
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (6)
1. Spoj, ili njegova farmaceutski prihvatljiva sol, gdje je spoj izabran iz grupe koju čine:
[image]
[image]
[image]
i
[image]
2. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je spoj (8S,11S,14S)-18-hidroksi-11-metil-14-[metil-[(2S)-2-[[4-amino-2-(4-terc-butilfenil)-6-metil-pirimidin-5 -karbonil] amino] -3 -(sulfamoilamino)propanoil]amino]-10,13-diokso-3,17-bis[(2R)-3-amino-2-hidroksi-propoksi]-9,12-diazatriciklo[13.3.1.12,6]ikoza-1(18),2(20),3,5,15(19),16-heksaen-8-karboksilna kiselina.
3. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je spoj (8S,11S,14S)-18-hidroksi-11-metil-14-[metil-[(2S)-4-amino-2-[[4-amino-2-(terc-butilfenil)-6-metil-pirimidin-5-karbonil]amino]butanoil]amino]-10,13-diokso-3,17-bis[(2R)-3-amino-2-hidroksi-propoksi]-9,12-diazatriciklo[13.3.1.12,6]ikoza-1(18),2(20),3,5,15(19),16-heksaen-8-karboksilna kiselina.
4. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je spoj (8S,11S,14S)-18-hidroksi-11-metil-14-[metil-[(2S)-4-amino-2-[[4-metil-2-[4-(1-metilciklopropil)fenil]pirimidin-5-karbonil]amino]butanoil]amino]-10,13-diokso-3,17-bis[(2R)-3-amino-2-hidroksi-propoksi]-9,12-diazatriciklo[13.3.1.12,6]ikoza-1(18),2(20),3,5,15(19),16-heksaen-8-karboksilna kiselina.
5. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje je spoj (8S,11S,14S)-18-hidroksi-11-metil-14-[metil-[(2S)-4-amino-2-[[2-(4-terc-butilfenil)-4-amino-6-difluorometil-pirimidin-5karbonil]amino]butanoil]amino]-10,13-diokso-3,17-bis[(2R)-3-amino-2-hidroksi-propoksi]-9,12-diazatriciklo[13.3.1.12,6]ikoza-1(18),2(20),3,5,15(19),16-heksaen-8-karboksilna kiselina.
6. Farmaceutski sastav koja sadrži spoj prema bilo kojem od zahtjeva 1-5, ili njegova farmaceutski prihvatljiva sol, i farmaceutski prihvatljiv ekscipijens.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962853457P | 2019-05-28 | 2019-05-28 | |
PCT/US2020/034670 WO2020243155A1 (en) | 2019-05-28 | 2020-05-27 | Macrocyclic broad spectrum antibiotics |
EP20814144.0A EP3968983B1 (en) | 2019-05-28 | 2020-05-27 | Macrocyclic broad spectrum antibiotics |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231497T1 true HRP20231497T1 (hr) | 2024-03-01 |
Family
ID=73551292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231497TT HRP20231497T1 (hr) | 2019-05-28 | 2020-05-27 | Makrociklični antibiotici širokog spektra |
Country Status (30)
Country | Link |
---|---|
US (2) | US11208387B2 (hr) |
EP (2) | EP3968983B1 (hr) |
JP (2) | JP7078807B2 (hr) |
KR (2) | KR102450071B1 (hr) |
CN (2) | CN115215923A (hr) |
AR (1) | AR119019A1 (hr) |
AU (2) | AU2020282975B2 (hr) |
BR (1) | BR112021024010A2 (hr) |
CA (1) | CA3141853A1 (hr) |
CL (1) | CL2021003153A1 (hr) |
CO (1) | CO2021017561A2 (hr) |
CR (1) | CR20210682A (hr) |
DK (1) | DK3968983T3 (hr) |
ES (1) | ES2961566T3 (hr) |
FI (1) | FI3968983T3 (hr) |
HR (1) | HRP20231497T1 (hr) |
HU (1) | HUE063847T2 (hr) |
IL (2) | IL295889A (hr) |
LT (1) | LT3968983T (hr) |
MA (1) | MA55981B1 (hr) |
MX (1) | MX2021014554A (hr) |
NZ (1) | NZ783605A (hr) |
PE (2) | PE20230383A1 (hr) |
PL (1) | PL3968983T3 (hr) |
PT (1) | PT3968983T (hr) |
RS (1) | RS64852B1 (hr) |
SG (1) | SG11202112920SA (hr) |
SI (1) | SI3968983T1 (hr) |
TW (2) | TWI815017B (hr) |
WO (1) | WO2020243155A1 (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6873993B2 (ja) | 2015-11-20 | 2021-05-19 | アールキューエックス ファーマシューティカルズ,インク. | 大環状広域抗生物質 |
KR102602837B1 (ko) * | 2021-03-08 | 2023-11-15 | 차의과학대학교 산학협력단 | 항독력활성을 가지는 화합물 |
CN113583003A (zh) * | 2021-08-05 | 2021-11-02 | 广东西捷药业有限公司 | 一种伐地那非类似物及其合成方法和应用 |
CN113933416B (zh) * | 2021-09-30 | 2023-10-10 | 海南海灵化学制药有限公司 | 一种注射用硫酸头孢匹罗中杂质的检测方法 |
WO2024102404A1 (en) | 2022-11-11 | 2024-05-16 | Genentech, Inc. | Enzymatic asymmetric syntheses of n-alkyl amino acids |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3128280A (en) | 1959-10-23 | 1964-04-07 | Searle & Co | 1-(alkoxylated/halogenated phenyl)-3-pyridylmethylureas |
US5204328A (en) | 1990-06-26 | 1993-04-20 | Merck & Co., Inc. | Peptides having atrial natriuretic factor activity |
JPH11514527A (ja) | 1995-11-03 | 1999-12-14 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | バキルス エスピー(Bacillus sp.)用の陽性選択ベクター |
PL194025B1 (pl) | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
EP0895999A1 (en) | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
GB9902399D0 (en) | 1999-02-03 | 1999-03-24 | Smithkline Beecham Plc | Compounds |
US6660832B1 (en) | 1999-08-20 | 2003-12-09 | Isis Pharmaceuticals, Inc. | Macrocyclic compounds and preparation methods thereof |
US6951840B2 (en) | 2001-08-31 | 2005-10-04 | Eli Lilly And Company | Lipoglycopeptide antibiotics |
DE10226921A1 (de) | 2002-06-17 | 2003-12-24 | Bayer Ag | Antibakterielle Amid-Makrozyklen |
EP1656390A2 (en) | 2003-07-17 | 2006-05-17 | Migenix Inc. | Compositions of lipopeptide antibiotic derivatives and methods of use thereof |
DE10358824A1 (de) | 2003-12-16 | 2005-07-21 | Bayer Healthcare Ag | Antibakterielle Makrozyklen mit substituiertem Biphenyl |
DE102005014245A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Antibakterielle Amid-Makrozyklen V |
DE102005014247A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Antibakterielle Amid-Makrozyklen VI |
KR20130044382A (ko) | 2010-03-01 | 2013-05-02 | 마이렉시스 인코포레이티드 | 화합물 및 그의 치료 용도 |
MX2012010381A (es) | 2010-03-09 | 2012-11-23 | Merck Canada Inc | Lipoglicopeptidos en puente que potencian la actividad de antibacterianos de beta-lactama. |
WO2011120071A1 (en) | 2010-04-01 | 2011-10-06 | The University Of Queensland | Oxytocin peptide analogues |
EP2616093A4 (en) | 2010-09-15 | 2014-02-26 | Scripps Research Inst | IN A WIDE SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGUE |
WO2012166665A2 (en) | 2011-05-27 | 2012-12-06 | Rqx Pharmaceuticals, Inc. | Broad spectrum antibiotics |
US10501493B2 (en) | 2011-05-27 | 2019-12-10 | Rqx Pharmaceuticals, Inc. | Broad spectrum antibiotics |
CN103159830B (zh) | 2011-12-15 | 2017-06-20 | 上海来益生物药物研究开发中心有限责任公司 | 脂肽类化合物 |
FR2986154B1 (fr) | 2012-01-31 | 2017-08-04 | Pierre Fabre Dermo-Cosmetique | Nouveau systeme photoprotecteur |
US20150045286A1 (en) * | 2012-03-14 | 2015-02-12 | The Scripps Research Institute | Broad spectrum antibiotic arylomycin analogs |
CN103788176A (zh) | 2012-10-31 | 2014-05-14 | 上海来益生物药物研究开发中心有限责任公司 | 一种arylomycin类化合物及其制备方法和应用 |
JP6437443B2 (ja) | 2012-11-21 | 2018-12-12 | アールキューエックス ファーマシューティカルズ,インク. | 大環状広域抗生物質 |
CN106661084B (zh) * | 2014-05-20 | 2021-08-31 | 阿奇克斯制药公司 | 大环广谱抗生素 |
ITUB20154591A1 (it) | 2015-10-12 | 2017-04-12 | Crestoptics S R L | Apparato di microscopia confocale e relativo procedimento di acquisizione ed elaborazione di immagini |
TWI725075B (zh) | 2015-11-20 | 2021-04-21 | 美商Rqx製藥公司 | 巨環廣效抗生素 |
JP6873993B2 (ja) * | 2015-11-20 | 2021-05-19 | アールキューエックス ファーマシューティカルズ,インク. | 大環状広域抗生物質 |
IL268483B2 (en) | 2017-02-15 | 2024-02-01 | Rqx Pharmaceuticals Inc | A macrocyclic antibiotic with a broad spectrum |
MX2019011517A (es) | 2017-03-27 | 2019-11-18 | Hoffmann La Roche | Proceso para producir analogos de anillo de arilomicina. |
MA50664A (fr) | 2017-09-29 | 2020-08-05 | Genentech Inc | Complexes d'antibiotiques peptidiques et leurs méthodes d'utilisation |
-
2020
- 2020-05-27 BR BR112021024010A patent/BR112021024010A2/pt unknown
- 2020-05-27 JP JP2021570324A patent/JP7078807B2/ja active Active
- 2020-05-27 TW TW109117701A patent/TWI815017B/zh active
- 2020-05-27 HR HRP20231497TT patent/HRP20231497T1/hr unknown
- 2020-05-27 NZ NZ783605A patent/NZ783605A/en unknown
- 2020-05-27 PE PE2021001977A patent/PE20230383A1/es unknown
- 2020-05-27 SG SG11202112920SA patent/SG11202112920SA/en unknown
- 2020-05-27 IL IL295889A patent/IL295889A/en unknown
- 2020-05-27 EP EP20814144.0A patent/EP3968983B1/en active Active
- 2020-05-27 MX MX2021014554A patent/MX2021014554A/es unknown
- 2020-05-27 AU AU2020282975A patent/AU2020282975B2/en active Active
- 2020-05-27 SI SI202030269T patent/SI3968983T1/sl unknown
- 2020-05-27 ES ES20814144T patent/ES2961566T3/es active Active
- 2020-05-27 LT LTEPPCT/US2020/034670T patent/LT3968983T/lt unknown
- 2020-05-27 WO PCT/US2020/034670 patent/WO2020243155A1/en active Application Filing
- 2020-05-27 EP EP23189412.2A patent/EP4289480A3/en active Pending
- 2020-05-27 US US16/884,679 patent/US11208387B2/en active Active
- 2020-05-27 TW TW112136650A patent/TW202404953A/zh unknown
- 2020-05-27 PE PE2023002563A patent/PE20240066A1/es unknown
- 2020-05-27 CR CR20210682A patent/CR20210682A/es unknown
- 2020-05-27 KR KR1020217042492A patent/KR102450071B1/ko active IP Right Grant
- 2020-05-27 MA MA55981A patent/MA55981B1/fr unknown
- 2020-05-27 CA CA3141853A patent/CA3141853A1/en active Pending
- 2020-05-27 DK DK20814144.0T patent/DK3968983T3/da active
- 2020-05-27 AR ARP200101493A patent/AR119019A1/es unknown
- 2020-05-27 PL PL20814144.0T patent/PL3968983T3/pl unknown
- 2020-05-27 IL IL288294A patent/IL288294B/en unknown
- 2020-05-27 PT PT208141440T patent/PT3968983T/pt unknown
- 2020-05-27 RS RS20231102A patent/RS64852B1/sr unknown
- 2020-05-27 KR KR1020227033626A patent/KR20220137165A/ko active IP Right Grant
- 2020-05-27 FI FIEP20814144.0T patent/FI3968983T3/fi active
- 2020-05-27 CN CN202210868626.9A patent/CN115215923A/zh active Pending
- 2020-05-27 HU HUE20814144A patent/HUE063847T2/hu unknown
- 2020-05-27 CN CN202080040183.3A patent/CN114007605B/zh active Active
-
2021
- 2021-11-26 CL CL2021003153A patent/CL2021003153A1/es unknown
- 2021-12-17 US US17/644,861 patent/US20220135528A1/en active Pending
- 2021-12-21 CO CONC2021/0017561A patent/CO2021017561A2/es unknown
-
2022
- 2022-05-19 JP JP2022082018A patent/JP2022137011A/ja active Pending
-
2023
- 2023-01-24 AU AU2023200369A patent/AU2023200369A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231497T1 (hr) | Makrociklični antibiotici širokog spektra | |
MA51747A (fr) | Formulation d'anticorps pharmaceutique à ph faible | |
AR051340A1 (es) | Compuesto de c(4)- metoximetil acil pirrolidina, su uso para preparar un medicamento, formulacion farmaceutica que lo comprende y proceso para prepararlo | |
CO5090830A1 (es) | Poliformo de un agente farmaceutico | |
PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
BRPI0815124A2 (pt) | Uso de um composto derivado de n-(2-tiazolil)-amida, composto, composição farmacêutica e cosmética contendo o mesmo | |
JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
EP3843705C0 (en) | PREPARATION OF NANOSUSPENSION COMPRISING NANOCRYSTALS OF ACTIVE PHARMACEUTICAL INGREDIENTS COMPRISING LITTLE OR NO STABILIZING AGENTS | |
EA202092159A1 (ru) | Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение | |
MA55033A (fr) | Formulation d'anticorps thérapeutique | |
MX2022000713A (es) | Derivados de bencenosulfonamida y usos de las mismas. | |
MY191183A (en) | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
IL285362A (en) | Oral formulations of biologically active peptide and uses thereof | |
EA202190532A1 (ru) | Ингибиторы аргиназы и способы их применения | |
MA53333A (fr) | Formulations pharmaceutiques d'anticorps masqués | |
DK4045038T3 (en) | New formulations of 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide | |
WO2020180093A3 (ko) | 오셀타미비르 함유 의약 조성물 | |
MA46513A (fr) | Nouvelle forme cristalline de 1,3-thiazol-5-ylméthyl[(2r,5r)-5-{[(2s)-2-[(méthyl{[2-(propan-2-yl)- 1,3-thiazol-4-yl]méthyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphénylhexan-2-yl]carbamate or cobicistat | |
EP3873441A4 (en) | A new use of the poloxamer as a pharmacologically active substance | |
EP4038062A4 (en) | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT | |
EP4065598A4 (en) | BIOTIN UNIT-CONJUGATED POLYPEPTIDES AND PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THEREOF | |
EP4088731A4 (en) | COMPOSITION CONTAINING A PEPTIDE OR PEPTIDE COMPOUND USED AS ACTIVE INGREDIENT, AND ITS MEDICAL USE | |
BR112021019388A2 (pt) | Forma cristalina, e composição farmacêutica | |
EP3939988A4 (en) | PHARMACEUTICAL COMPOSITION WITH NOVEL HETEROCYCLIC AZOLOPYRIMIDINE COMPOUND AS THE ACTIVE SUBSTANCE | |
BRPI0401742B8 (pt) | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |